A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)

PHASE2CompletedINTERVENTIONAL
Enrollment

466

Participants

Timeline

Start Date

June 9, 2021

Primary Completion Date

May 24, 2024

Study Completion Date

August 1, 2025

Conditions
Alzheimer's Disease
Interventions
OTHER

Placebo

"* Pharmaceutical form: Solution for infusion~* Route of administration: Intravenous infusion~Participants will receive Placebo during the Double-blind Treatment Period."

BIOLOGICAL

Bepranemab

"* Pharmaceutical form: Solution for infusion~* Route of administration: Intravenous infusion~Participants will receive pre-specified doses of bepranemab during the Double-blind Treatment Period and the Open-label Extension Period."

Trial Locations (103)

22031

Ah0003 50424, Fairfax

23507

Ah0003 50432, Norfolk

30033

Ah0003 50479, Decatur

32127

Ah0003 50457, Port Orange

32502

Ah0003 50438, Pensacola

32503

Ah0003 50623, Pensacola

32751

Ah0003 50426, Maitland

33016

Ah0003 50436, Hialeah

33125

Ah0003 50427, Miami

33155

Ah0003 50446, Westchester

33180

Ah0003 50449, Aventura

33407

Ah0003 50444, West Palm Beach

33409

Ah0003 50476, West Palm Beach

33445

Ah0003 50430, Delray Beach

33462

Ah0003 50465, Atlantis

33487

Ah0003 50435, Boca Raton

33613

Ah0003 50454, Tampa

33912

Ah0003 50429, Fort Myers

34105

Ah0003 50478, Naples

34761

Ah0003 50464, Ocoee

38018

Ah0003 50455, Cordova

45219

Ah0003 50451, Cincinnati

55130

Ah0003 50448, Saint Paul

77054

Ah0003 50380, Houston

90807

Ah0003 50458, Long Beach

91106

Ah0003 50452, Pasadena

92123

Ah0003 50447, San Diego

92614

Ah0003 50442, Irvine

92705

Ah0003 50434, Santa Ana

92835

Ah0003 50431, Fullerton

93710

Ah0003 50428, Fresno

94303

Ah0003 50450, Palo Alto

98007

Ah0003 50440, Bellevue

06510

Ah0003 50422, New Haven

Ah0003 50467, New Haven

06905

Ah0003 50421, Stamford

02184

Ah0003 50445, Braintree

02459

Ah0003 50453, Newton

07753

Ah0003 50420, Neptune City

02914

Ah0003 50423, East Providence

Unknown

Ah0003 40123, Brussels

Ah0003 40575, Brussels

Ah0003 40576, Kortrijk

Ah0003 40002, Leuven

Ah0003 50463, Kelowna

Ah0003 50461, Ottawa

Ah0003 50520, Québec

Ah0003 50045, Toronto

Ah0003 50291, Toronto

Ah0003 50462, Toronto

Ah0003 50522, West Vancouver

Ah0003 40129, Bordeaux

Ah0003 40580, Bron

Ah0003 40493, Marseille

Ah0003 40635, Nantes

Ah0003 40578, Paris

Ah0003 40201, Rennes

Ah0003 40581, Toulouse

Ah0003 40579, Villeurbanne

Ah0003 40028, Berlin

Ah0003 40430, Munich

Ah0003 40371, Monza

Ah0003 40600, Parma

Ah0003 40597, Pavia

Ah0003 40438, Roma

Ah0003 40596, Rome

Ah0003 40598, Rome

Ah0003 40449, 's-Hertogenbosch

Ah0003 40450, Amsterdam

Ah0003 40601, Zwolle

Ah0003 40603, Bialystok

Ah0003 40606, Bydgoszcz

Ah0003 40605, Katowice

Ah0003 40609, Katowice

Ah0003 40774, Katowice

Ah0003 40608, Szczecin

Ah0003 40638, Ścinawa

Ah0003 40602, Warsaw

Ah0003 40604, Warsaw

Ah0003 40607, Warsaw

Ah0003 40611, Wroclaw

Ah0003 40159, Barcelona

Ah0003 40160, Barcelona

Ah0003 40267, Barcelona

Ah0003 40612, Barcelona

Ah0003 40105, Córdoba

Ah0003 40614, Donostia / San Sebastian

Ah0003 40540, Madrid

Ah0003 40615, Madrid

Ah0003 40352, Pamplona

Ah0003 40280, Sant Cugat del Vallès

Ah0003 40049, Seville

Ah0003 40453, Terrassa

Ah0003 40230, Valencia

Ah0003 40613, Valencia

Ah0003 40616, Zaragoza

Ah0003 40662, Birmingham

Ah0003 40619, Bristol

Ah0003 40622, Guildford

Ah0003 40618, London

Ah0003 40621, London

Ah0003 40623, Plymouth

Ah0003 40691, Winchester

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY